Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose

Journal of Clinical Pharmacology

Volumn 52, Issue 8, 2012, Pages 1240-1247

  Lettieri, John T ^a   Scheerans, Christian ^b   Blunck, Martin ^b   Mazzu, Arthur L ^a   Frey, Reiner ^b   Mück, Wolfgang ^b   Sundaresan, Pavur R ^a  

^a Bayer HealthCare Pharmaceuticals Inc   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

Cinaciguat; hematocrit; pharmaco kinetics; renal impairment; soluble guanylate cyclase activator

Indexed keywords

CINACIGUAT;

ACUTE HEART FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; BENZOATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GUANYLATE CYCLASE; HALF-LIFE; HEART FAILURE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENAL INSUFFICIENCY;

EID: 84864398365     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011410567     Document Type: Article

References (17)

1. Frey R, Muck W, Unger S, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008 ; 48: 1400-1410
2. Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 ; 119: 2781-2788
3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 ; 29: 2388-2442
4. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009 ; 53: e1 - e90
5. Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006 ; 5: 755-768 (Pubitemid 44323702)
6. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest. 2005 ; 115: 509-517 (Pubitemid 40322220)
7. Mueck W, Frey R. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Clin Pharmacokinet. 2010 ; 49: 119-129
8. WittkeKMueckWFreyR. Metabolism and excretion of cinaciguat, an oral soluble guanylate cyclase activator, in rats, dogs, and humans. Drug Metab Dispos. Unpublished Manuscript.
9. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther. 2009 ; 86: 475-479
10. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev. 2007 ; 12: 91-95 (Pubitemid 46916953)
11. Schuhmacher J, Buhner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci. 2000 ; 89: 1008-1021
12. Rowland M, Tozer T Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Philadelphia, PA: Lippincott Williams & Wilkins ; 2010 :
13. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos. 2007 ; 35: 501-502 (Pubitemid 46333921)
14. Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984 ; 69: 57-64 (Pubitemid 14215862)
15. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 ; 52: 1527-1539
16. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007 ; 13: 599-608 (Pubitemid 47513536)
17. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006 ; 47: 1987-1996